|
Back to List
|
Title:
Author:
Date:
Source:
|
Gabapentin in the prophylaxis of migraine:
a double-blind, randomized, placebo-controlled study
D. Mei
Posted November 2000
Cephalalgia, May 2000
|
Objective: Gabapentin is a new generation antiepileptic drug that increases brain GABA levels. We report the results of a 3-month, randomized, double-blind, placebo-controlled study on the effects of gabapentin in the prophylaxis of patients with migraine meeting the IHS criteria.
Conclusion: No patient withdrew and gabapentin was well tolerated. Adverse events occurred in only 13 patients (27%) and those that did occur (somnolence, dizziness, tremor, fatigue and ataxia) were generally transient and mild to moderate in severity. At the end of the treatment there was a significant reduction in frequency and intensity of migraine in 30 patients treated with gabapentin.
|
